Advertisement
ACB vs TLRY
Which Stock Would AI Choose? Aurora Cannabis (ACB) vs. Tilray Brands (TLRY) Stock Comparison
Key Takeaways
- Aurora Cannabis (ACB) is a Canadian medical-cannabis producer whose shares have surged on a board-approved acquisition by Organigram Global at a significant premium to its prior trading level.
- Tilray Brands (TLRY) is a larger, diversified consumer-packaged-goods company spanning cannabis, beverages, and wellness, but its cannabis segment revenue has contracted while its shares remain far below their 52-week high.
- ACB reported record international medical-cannabis revenue and holds a debt-free balance sheet, while TLRY posted a net loss despite strong beverage growth.
- Relative performance has diverged sharply: ACB has benefited from merger-and-acquisition (M&A) momentum, whereas TLRY has faced downward earnings-estimate revisions and a "Sell" style consensus rating.
- Tickeron AI Verdict: Based on trend consistency, a clearly defined M&A catalyst, and balance-sheet strength, Tickeron's AI currently favors ACB over TLRY in this comparison.
- For deeper coverage, explore ACB Major News and ACB Today's Price Move, as well as TLRY Major News and TLRY Today's Price Move.
- Interested in automated, data-driven market insights? Explore the curated Trending AI Robots.
Introduction
Investors tracking the cannabis and broader consumer sectors often weigh Aurora Cannabis (ACB) against Tilray Brands (TLRY) as two of the most widely followed publicly traded names in the space. Although both carry cannabis exposure, they operate very different business models, and their recent market positioning has diverged meaningfully. This stock comparison is particularly relevant for traders assessing relative performance and for investors evaluating growth drivers, balance-sheet quality, and M&A catalysts. By examining business structure, recent momentum, risk factors, and sentiment, this article provides an objective framework for understanding which of these two tickers currently exhibits stronger relative positioning.
ACB Overview and Recent Performance
Aurora Cannabis (ACB) is a Canadian medical-cannabis company that has increasingly focused on international markets while winding down its consumer channel. In recent weeks, the defining development has been corporate activity: after rejecting an unsolicited, hostile takeover approach from Curaleaf, Aurora's board agreed to be acquired by Organigram Global in a deal valued at roughly C$561 million, offering C$7.80 per share. The announcement triggered a sharp rally, reflecting a premium to the company's prior trading range and renewed investor attention on consolidation across the sector.
Fundamentally, Aurora reported fiscal second-quarter net revenue of approximately C$86 million, up 9% year over year, led by a record C$61.4 million in international medical-cannabis revenue — a 44% increase driven by Germany and Poland. The company generated adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of about C$14 million and improved its free-cash-flow outflow by roughly C$22 million. Its balance sheet remains notable: about C$133 million in cash and short-term investments with no debt. Sentiment has been supported by this mix of M&A momentum, international growth, and balance-sheet stability.
TLRY Overview and Recent Performance
Tilray Brands (TLRY) is a diversified global lifestyle and consumer-packaged-goods company operating across cannabis, beverages, wellness, and distribution in North America, Europe, and Latin America. In recent market activity, the company has emphasized cost discipline and operational consolidation. It announced a plan to strengthen its Canadian cannabis operations by consolidating cultivation and pre-roll production, projecting roughly US$10 million in annualized savings, alongside an additional US$20 million savings program in its U.S. beverage business.
Fiscally, Tilray reported first-quarter net revenue of about US$257 million, up 23% year over year, with gross margin improving from 27% to 30%. Growth was led by beverages, where revenue rose 82% to roughly US$101.5 million, while distribution revenue increased 14%. Cannabis revenue, however, declined to approximately US$56 million from US$64.5 million a year earlier, and the company posted a net loss of US$40 million. The shares have traded well below their 52-week high, and analyst views remain mixed, with some firms maintaining cautious ratings amid concerns over profitability and valuation.
Trending AI Robots
For traders seeking a systematic edge, Tickeron's Trending AI Robots page offers a curated view of its most compelling automated trading strategies. Tickeron hosts hundreds of AI trading bots that collectively monitor and trade thousands of different tickers, but only the strategies best suited to current market conditions earn a place in this focused section. These bots span a range of trading styles, timeframes, risk profiles, performance statistics, and target tickers, allowing users to evaluate approaches that align with their own objectives. The curated selection is designed to surface the highest-conviction strategies rather than an exhaustive list, helping investors cut through noise. Exploring the Trending AI Robots can be a practical next step for anyone interested in data-driven market positioning.
Head-to-Head Comparison
The two companies diverge most clearly on business model and growth drivers. Aurora (ACB) is a pure-play medical-cannabis operator concentrated on international markets, which has yielded high-margin revenue growth but leaves it sensitive to regulatory changes such as Canada's reimbursement adjustments. Tilray (TLRY) is a diversified conglomerate whose beverage and distribution segments provide revenue scale and some insulation from cannabis-specific volatility, but whose core cannabis segment has been shrinking.
On momentum and catalysts, Aurora holds a concrete, near-term driver in its pending acquisition, which has re-rated the stock sharply. Tilray's catalysts are more operational — cost savings, beverage growth, and a U.S. brewery and distribution partnership — and have yet to translate into sustained share-price recovery. Risk profiles also differ: Aurora's outlook now depends heavily on deal completion, while Tilray's depends on improving profitability across a broader, more capital-intensive portfolio. In terms of market sentiment, Aurora has enjoyed a clearer positive inflection, whereas Tilray continues to face mixed analyst ratings and downward revisions to earnings estimates.
Tickeron AI Verdict
Weighing observable factors such as trend consistency, catalyst clarity, and relative positioning, Tickeron's AI currently leans toward ACB over TLRY in this comparison. Aurora's recent momentum is anchored by a defined M&A catalyst and a premium takeover price, supported by record international medical revenue and a debt-free balance sheet. Tilray, while larger and more diversified, presents a more mixed picture with contracting cannabis revenue, ongoing net losses, and a stock trading well below prior highs. This assessment is probabilistic rather than definitive: it reflects current trend structure and catalysts, and relative positioning can shift as new data and market conditions emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a StrongBuy and TLRY is a Buy.
ACB's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ACB turned positive on November 03, 2026. Looking at past instances where ACB's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on ACB as a result. In 71 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
ACB moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ACB crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +24.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in 180 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 74 of 116 cases where ACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for ACB moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In 17 of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
ACB broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.629) is normal, around the industry mean (6.379). P/E Ratio (-2.701) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.984) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
TLRY's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for TLRY turned positive on November 04, 2026. Looking at past instances where TLRY's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TLRY's RSI Oscillator exited the oversold zone, 37 of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +16.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLRY as a result. In 71 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TLRY entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (6.379). P/E Ratio (-2.679) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
ACB | TLRY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 91 | 10 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 22 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 93 | |
PRICE GROWTH RATING 1..100 | 37 | 88 | |
P/E GROWTH RATING 1..100 | 98 | 14 | |
SEASONALITY SCORE 1..100 | 22 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TLRY's Valuation (22) in the Biotechnology industry is in the same range as ACB (24) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to ACB’s over the last 12 months.
TLRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ACB (100) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to ACB’s over the last 12 months.
TLRY's SMR Rating (93) in the Biotechnology industry is in the same range as ACB (96) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to ACB’s over the last 12 months.
ACB's Price Growth Rating (37) in the Pharmaceuticals Other industry is somewhat better than the same rating for TLRY (88) in the Biotechnology industry. This means that ACB’s stock grew somewhat faster than TLRY’s over the last 12 months.
TLRY's P/E Growth Rating (14) in the Biotechnology industry is significantly better than the same rating for ACB (98) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew significantly faster than ACB’s over the last 12 months.
| ACB | TLRY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 80% |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 79% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 79% | 2 days ago 89% |
| Advances ODDS (%) | 10 days ago 77% | 10 days ago 79% |
| Declines ODDS (%) | 2 days ago 84% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 82% | N/A |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACB’s FA Score shows that 1 FA rating(s) are green while TLRY’s FA Score has 2 green FA rating(s).
- ACB’s FA Score: 1 green, 4 red.
- TLRY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACB’s TA Score shows that 6 TA indicator(s) are bullish while TLRY’s TA Score has 4 bullish TA indicator(s).
- ACB’s TA Score: 6 bullish, 4 bearish.
- TLRY’s TA Score: 4 bullish, 3 bearish.
Price Growth
ACB (@Pharmaceuticals: Generic) experienced а -3.85% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was -11.39% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.98%. For the same industry, the average monthly price growth was -6.01%, and the average quarterly price growth was +6.11%.
Reported Earning Dates
ACB is expected to report earnings on Feb 10, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.98% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
ACB and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACB has been closely correlated with CGC. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if ACB jumps, then CGC could also see price increases.
| Ticker / NAME | Correlation To ACB | 1D Price Change % | ||
|---|---|---|---|---|
| ACB | 100% | -1.19% | ||
| CGC - ACB | 69% Closely correlated | -5.16% | ||
| SNDL - ACB | 65% Loosely correlated | -2.11% | ||
| TLRY - ACB | 62% Loosely correlated | -4.60% | ||
| TRLV - ACB | 58% Loosely correlated | -0.71% | ||
| OGI - ACB | 55% Loosely correlated | -2.31% | ||
More | ||||
TLRY and
Correlation & Price change
A.I.dvisor indicates that over the last year, TLRY has been closely correlated with SNDL. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if TLRY jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To TLRY | 1D Price Change % | ||
|---|---|---|---|---|
| TLRY | 100% | -4.60% | ||
| SNDL - TLRY | 76% Closely correlated | -2.11% | ||
| CGC - TLRY | 75% Closely correlated | -5.16% | ||
| ACB - TLRY | 65% Loosely correlated | -1.19% | ||
| CRON - TLRY | 64% Loosely correlated | -1.16% | ||
| GLAS - TLRY | 59% Loosely correlated | -33.16% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| GLM.X | 0.101844 | 0.001318 | +1.31% |
| Golem cryptocurrency | |||
| STEEM.X | 0.045805 | -0.000194 | -0.42% |
| Steem cryptocurrency | |||
| LINK.X | 10.131871 | -0.061294 | -0.60% |
| Chainlink cryptocurrency | |||
| HOOK.X | 0.000598 | -0.000018 | -2.90% |
| Hooked Protocol cryptocurrency | |||
| RARE.X | 0.009946 | -0.000460 | -4.42% |
| SuperRare cryptocurrency | |||